Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF), a drug discovery company focused on creating next-generation psychedelic medicines to treat neurological and psychiatric disorders, announced that its lead candidate MSP-1014 was comparable to psilocybin assessed using a drug discrimination assay.
The Toronto-based company said the results suggest that MSP-1014 induces a “similar perceptual state to psilocybin, further confirming the viability of MSP-1014 as a therapeutic analog of first-generation psilocybin” as the company advances MSP-1014 into the clinic.
“In the drug discrimination assay, MSP-1014 demonstrated a dose-dependent and full generalization to a psilocybin discriminative cue in rats,” Mindset Pharma Chief Scientific Officer Joseph Araujo said in a statement.
READ: Mindset Pharma selects Treatment-Resistant Depression and End of Life Cancer Angst as initial target indications for MSP-1014
“Furthermore, we identified an effective dosage of 0.6 mg/kg for subcutaneous administration of MSP-1014 with no detrimental effect on the response rate up to doses of 2 mg/kg. MSP-1014 also showed a dose-dependent generalization to a psilocybin cue following the oral route of administration. These results further validate MSP-1014 as an effective second-generation psilocybin-like drug candidate,” he added.
MSP-1014 is a novel patent-pending drug candidate that, based on preclinical data, shows potential to be a safer second-generation psilocybin-like therapy with decreased potential for side effects. The company has selected Treatment-Resistant Depression (TRD) and End of Life Cancer Angst as initial target indications for its lead clinical candidate MSP-1014.
Mindset Pharma said it continues to perform studies across various preclinical models with MSP-1014 and its library of next-generation psychedelic compounds.
“Our goal is to show the differentiation of our novel drug candidates and build a catalog of translational data as we prepare for human clinical trials,” said Mindset Pharma CEO James Lanthier.
Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive
